Contents -- Foreword -- Preface -- About the Authors -- Chapter 1 Introduction -- Chapter 2 What Is Cancer? -- 2.1. Historical Background -- 2.2. Characteristics of Tumors -- 2.3. Origin of Cancer -- 2.4. Environmental Agents -- 2.4.1. Radiation -- 2.4.2. Chemical carcinogens -- 2.4.3. Oncogenic viruses -- 2.4.4. Heredity -- 2.5. Pathology -- 2.6. Grading -- 2.7. Staging -- 2.8. Surgery -- 2.8.1. Various forms of cancer surgery -- 2.8.1.1. Laparoscopic surgery -- 2.8.1.2. Robotic surgery -- 2.8.1.3. Radiofrequency ablation (RFA) -- 2.9. Radiation Therapy -- 2.9.1. Types of radiation therapy -- 2.9.1.1. Brachytherapy -- 2.9.1.2. Conformal radiotherapy -- 2.9.1.3. Stereotactic radiosurgery -- 2.9.1.4. Proton beam therapy -- 2.9.1.5. Neutron capture therapy -- 2.10. Chemotherapy -- 2.10.1. Common chemotherapeutic agents -- 2.10.1.1. Alkylating agents -- 2.10.1.2. Antimetabolites -- 2.10.1.3. Mitotic inhibitors -- 2.10.1.4. Topoisomerase inhibitors -- 2.10.1.5. Anthracyclines -- 2.11. Hematopoietic Stem Cell Transplantation -- 2.12. Hormonal Therapy -- 2.13. Biological Therapies -- 2.13.1. Types of biological therapies -- 2.13.1.1. Monoclonal antibodies -- 2.13.1.2. Angiogenesis inhibitors -- 2.13.1.3. Tyrosine kinase inhibitors -- 2.13.1.4. Proteasome inhibitors -- 2.13.1.5 mTOR inhibitors -- 2.13.1.6. Immunotherapy -- 2.14. Clinical Trials -- 2.15. Long-Term Survival -- 2.16. Prevention -- Chapter 3 Principles of Neutron Capture Therapy -- 3.1. Boron Neutron Capture Therapy (BNCT) -- 3.2. Gadolinium Neutron Capture Therapy (GdNCT) -- Chapter 4 Major Neutron Capture Therapy (NCT) Drug Prototypes -- 4.1. BNCT Agents: Background and General Requirements -- 4.1.1. Blood brain barrier (BBB) -- 4.1.2. Drug delivery methods -- 4.2. Boron Compounds-Based BNCT Agents -- 4.2.1. Clinically used boron compounds -- 4.2.2. Boronated polyamines as BNCT agents.

4.2.3. Boronated amino acids and peptides as BNCT agents -- 4.2.4. Boronated nucleic acids as BNCT agents -- 4.2.5. Boronated carbohydrates as BNCT agents -- 4.2.6. Phosphorus-containing boron compounds as BNCT agents -- 4.2.7. Other boron-containing compounds as BNCT agents -- 4.3. Boron-Containing Nanomaterial-Based BNCT Agents -- 4.3.1. Liposomes -- 4.3.2. Dendrimers and dendritic polymers as BNCT agents -- 4.3.3. Boronated carbon nanotubes as BNCT agents -- 4.3.4. Boron nanotubes as BNCT agents -- 4.3.5. Boronated magnetic nanoparticles as BNCT agents -- 4.4. Major Gadolinium Neutron Capture Therapy Drug Types -- 4.4.1. GdNCT agents -- 4.5. Combined Gadolinium and Boron Neutron Capture Therapy (GdBNCT) Agents -- Chapter 5 Neutron Sources for NCT -- 5.1. Introduction -- 5.2. Fission-Based Reactors -- 5.3. Accelerator-Based Neutron Sources -- 5.4. Other Neutron Sources -- 5.4.1. Fusion-based neutron generators -- 5.4.2. Spallation-based systems -- 5.4.3. Isotope decay processes -- Chapter 6 NCT Dosimetry and Treatment Planning -- 6.1. BNCT Dosimetry -- 6.2. GdNCT Dosimetry -- Chapter 7 Selected in vitro and in vivo Studies -- 7.1. In vivo and in vitro Studies Involving BNCT -- 7.2 In vivo and in vitro Studies Involving GdNCT -- 7.2.1 In vitro studies involving GdNCT -- 7.2.2. In vivo studies involving GdNCT -- 7.3. In vitro and in vivo Studies Involving Combined BNCT and GdNCT -- Chapter 8 Clinical Trials -- 8.1. Clinical Trials Using Boron Neutron Capture Therapy (BNCT) -- 8.1.1. Clinical trials in the United States of America -- 8.1.1.1. Early clinical trials in the USA -- 8.1.1.2. Later clinical trials in the USA -- 8.1.2. Clinical trials in Japan -- 8.1.3. Clinical trials in Finland -- 8.1.4. Clinical trials in Sweden -- 8.1.5. Other clinical trials -- 8.2. Clinical Trials Using Gadolinium Neutron Capture Therapy (GdNCT).

Chapter 9 Future Perspectives for Boron and Gadolinium Neutron Capture Therapies in Cancer Treatment -- Appendix: The Clinical State of BNCT by US Department of Energy (DOE) as at 1997 -- Bibliography -- Index.